Merck & Co, INC Form 4 insider transactions

Merck & Co., Inc. Director Stephen Mayo acquired 2,863.0921 phantom stock units on May 30, 2025, increasing his total beneficial ownership of phantom stock to 12,539.8325 units.

Merck & Co., Inc. Director Risa J. Lavizzo-Mourey reported the acquisition of 2,863.0921 phantom stock units as part of her compensation plan, increasing her total beneficial ownership of phantom stock to 15,367.349 units.

Merck & Co., Inc. Director Surendralal L. Karsanbhai acquired 2,863.0921 phantom stock units, valued at $76.84 per unit, as part of a deferred compensation plan.

Merck & Co., Inc. Director Thomas H. Glocer reported the acquisition of 5,100 shares of common stock and 2,863.0921 phantom stock units on May 30, 2025, as disclosed in a recent SEC Form 4 filing.

Merck & Co., Inc. Director Pamela J. Craig reported an acquisition of 2,863.0921 phantom stock units and updated her direct common stock holdings to 1,715 shares, alongside total phantom stock holdings of 31,990.792 units.

Merck & Co., Inc. Director Mary Ellen Coe has reported the acquisition of 10 shares of common stock and 2,863.0921 phantom stock units, increasing her beneficial ownership.

Merck & Co., Inc. Director Douglas M. Baker Jr. reported the acquisition of 2,863.0921 phantom stock units as part of a pre-scheduled 10b5-1 plan, effective May 30, 2025, alongside a direct holding of 16,000 common shares.

Dalton E. Smart III, SVP Fin. Global Controller at Merck & Co., Inc., reported transactions involving common stock and restricted stock units on May 3, 2025.

Joseph Romanelli, President of Human Health International at Merck & Co., Inc., reports the acquisition and disposal of common stock and restricted stock units.

SVP Fin. Global Controller of Merck & Co., Dalton E. Smart III, reports transactions involving common stock and restricted stock units.

EVP and Chief HR Officer of Merck & Co., Betty Larson, reports the acquisition and disposal of common stock and restricted stock units on April 30, 2025.

Joseph Romanelli, President of Human Health International at Merck, files an amended Form 4 to correct the number of common stock shares beneficially owned as of April 29, 2025.

Betty D. Larson, EVP and Chief HR Officer at Merck & Co., Inc., files an amendment to a previous Form 4 to correct the reported number of securities beneficially owned.

Dalton E. Smart III, SVP Fin. Global Controller at Merck & Co., Inc., reported the acquisition of stock options and restricted stock units on April 29, 2025.

Caroline Litchfield, EVP & CFO of Merck & Co., Inc., reports the acquisition of restricted stock units and stock options.

David Michael Williams, EVP, Chief Info&Digital Officer at Merck & Co., Inc., reports acquisition of stock options and restricted stock units.

Sanat Chattopadhyay, an Executive Vice President at Merck, reports acquisitions of restricted stock units and stock options, as well as holdings in grantor retained annuity trusts.

Richard R. DeLuca Jr., EVP & President of Merck Animal Health, reports acquisition of restricted stock units and stock options in a recent SEC filing.

Merck's CEO, Robert M. Davis, reports acquisition of stock options and restricted stock units in a recent SEC filing.

Johannes Oosthuizen, President, U.S. Market at Merck & Co., Inc., reports acquisition of restricted stock units and stock options.

Dean Y. Li, Executive VP & President, MRL at Merck & Co., Inc., reports the acquisition of stock options and restricted stock units.

EVP and General Counsel of Merck & Co., Inc., Jennifer Zachary, reports acquisition of restricted stock units and stock options.

Cristal N. Downing, Chief Communications & Public Affairs Officer at Merck & Co., reports the acquisition of restricted stock units and stock options.

EVP and Chief HR Officer of Merck & Co., Betty Larson, reports the acquisition of restricted stock units and stock options.

Chief Marketing Officer Chirfi Guindo reports acquisition of restricted stock units and stock options in Merck & Co., Inc.

Joseph Romanelli, President of Human Health International at Merck & Co., Inc., reports acquisition of restricted stock units and stock options.

Dalton E. Smart III, SVP Fin. Global Controller at Merck & Co., Inc., exercised stock options and sold shares on April 25, 2025.

Christine E. Seidman, a director at Merck & Co., Inc., reported the acquisition of phantom stock units settled in cash, according to a recent SEC Form 4 filing.

Director Thomas H. Glocer reports acquisition of phantom stock units and disposition of common stock.

Mary Ellen Coe, a director at Merck & Co., reported the acquisition of phantom stock units on March 31, 2025.